LYRA — Lyra Therapeutics Share Price
Last trade - 00:00- $1.15m
- -$14.74m
- $0.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -116.69% | ||
| Return on Equity | -6594.98% | ||
| Operating Margin | -7794.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.28 | 1.36 | 1.56 | 1.53 | 0.4 | 0.7 | 11.46 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Directors
- Maria Palasis PRE (56)
- Jason Cavalier CFO (48)
- Pamela Nelson SVP (51)
- Corinne Noyes SVP (53)
- Robert Richard SVP
- Michael Altman IND (39)
- Edward Anderson IND (71)
- C. Ann Merrifield IND (70)
- Konstantin Poukalov IND (35)
- W. Bradford Smith IND (65)
- Nancy Snyderman IND (69)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- November 21st, 2005
- Public Since
- May 1st, 2020
- No. of Shareholders
- 48
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,774,882
- Address
- 480 Arsenal Way, WATERTOWN, 02472
- Web
- https://lyratherapeutics.com/
- Phone
- +1 6173734600
- Auditors
- BDO USA, LLP
Upcoming Events for LYRA
Similar to LYRA
ABPRO Holdings
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adaptin Bio
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
FAQ
As of Today at 21:51 UTC, shares in Lyra Therapeutics are trading at $0.65. This share price information is delayed by 15 minutes.
Shares in Lyra Therapeutics last closed at $0.65 and the price had moved by -84.69% over the past 365 days. In terms of relative price strength the Lyra Therapeutics share price has underperformed the S&P500 Index by -88.31% over the past year.
The overall consensus recommendation for Lyra Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLyra Therapeutics does not currently pay a dividend.
Lyra Therapeutics does not currently pay a dividend.
Lyra Therapeutics does not currently pay a dividend.
To buy shares in Lyra Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.65, shares in Lyra Therapeutics had a market capitalisation of $1.15m.
Here are the trading details for Lyra Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LYRA
Based on an overall assessment of its quality, value and momentum Lyra Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lyra Therapeutics is $16.00. That is 2361.54% above the last closing price of $0.65.
Analysts covering Lyra Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$7.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lyra Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -91.98%.
As of the last closing price of $0.65, shares in Lyra Therapeutics were trading -86.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lyra Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lyra Therapeutics' management team is headed by:
- Maria Palasis - PRE
- Jason Cavalier - CFO
- Pamela Nelson - SVP
- Corinne Noyes - SVP
- Robert Richard - SVP
- Michael Altman - IND
- Edward Anderson - IND
- C. Ann Merrifield - IND
- Konstantin Poukalov - IND
- W. Bradford Smith - IND
- Nancy Snyderman - IND